Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of a phase 2 trial of monotherapy with the anti-CD38 monoclonal antibody, daratumumab, in patients with multiple myeloma who have received at least three different lines of therapy or who are double refractory.